FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | |
|--------------------------|----------|-------|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | |
| houre por | rocnonco | . 0.5 | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Patel Sanj K | | | | | <u>K</u> | 2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals International, plc KNSA] | | | | | | | C [(Che | 5. Relationship of Reporti (Check all applicable) Director Officer (give title | | | 10% Owne | | |
|---|---|--|---------------------------------------|---|------------------|--|--|---|--|------------------------------------|---------------------------------|------------------------------|---|---|--|--|--|--|--|
| (Last) | , | irst) REET, THIRD F | (Middle) | | | 3. Date of Earliest Transaction (Month/Day/Year) 07/23/2024 | | | | | | | | Officer (give title below) CHAIRMAN & CEO | | | | | |
| (Street) | | | W1S 4F | PZ | 4. | 4. If Amendment, Date of | | | | of Original Filed (Month/Day/Year) | | | | ndividual or Joint/Group Filin e) Form filed by One Rep Form filed by More tha Person | | | rting Pers | on | |
| (City) | (S | itate) | (Zip) | | R | Rule 10b5-1(c) | | | | ารลด | ction Indi | ication | | | | | | | |
| | | | | | | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | | |
| | | Та | ble I - N | lon-Der | rivativ | ve Se | curi | ties Ac | quire | d, D | isposed o | f, or Be | neficially | Owned | | | | | |
| | | 2. Transaction Date (Month/Day/Year) | | 2A. Deemed Execution Date, if any (Month/Day/Year) | | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and | | | Beneficially Owned Following | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | | | |
| | | | | | | | | Code | v | Amount | (A) or (D) | Price | Reported Transaction(s) (Instr. 3 and 4) | | | | (Instr. 4) | | |
| Class A Ordinary Share 07/ | | | 07/23/ | 3/2024 | | | | M | | 136,124 | A | \$1.59 | 199,136 | | Γ | | | | |
| Class A Ordinary Share 07/2 | | | 07/23/ | 7/23/2024 | | | | S ⁽¹⁾ | | 23,075 | D | \$23.25 | 176,061 | | Ε | | | | |
| Class A Ordinary Share 07/2 | | | 07/23/ | 07/23/2024 | | | | S ⁽¹⁾ | | 50,000 | D | \$25.05(2) | 126,061 | | D | | | | |
| Class A Ordinary Share 07/23 | | /2024 | 2024 | | | S ⁽¹⁾ | | 63,049 | D | \$27.01 ⁽³⁾ | 63,012 | | D | | | | | | |
| Class A Ordinary Share | | | | | | | | | | | | 109,795 | | I 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | | Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016 | | | |
| | | | Table I | | | | | | | | posed of, , convertil | | | Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | Date Execution Month/Day/Year) if any | | | ection Instr. | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exerc Expiration D (Month/Day/ | | ate | of Securi Underlyir | ng e Security nd 4) | 8. Price of Derivative Security (Instr. 5) | 9. Numl derivati Securiti Benefic Owned Followi Reporte Transac | ve ies ially ng | 10. Ownersh Form: Direct (D or Indirect (I) (Instr. | Beneficial Ownership ct (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exerci | sable | Expiration Date | Title | Amount or Number of Shares | | (Instr. 4 | | | | |
| Share Option | \$1.59 | 07/23/2024 | | | M ⁽¹⁾ | | | 136,124 | (4 | 1) | 12/15/2025 | Class A Ordinary Share | 136,124 | \$0 | 189, | ,147 | D | | |

Explanation of Responses:

- 1. This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.
- 2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between \$25.00 and \$25.75. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price
- 3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between \$27.00 and \$27.07. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price
- 4. The option is fully vested and exercisable.

/s/ Madelyn Zeylikman, 07/25/2024 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.